Objective: To analyze occurrence of falls among patients with partial seizures, with/ without secondarily generalized seizures (SGS), and primary generalized tonic-clonic seizures (PGTCS) in the perampanel phase III clinical studies. Methods: Studies 304, 305, and 306 randomized subjects (≥12 years) with drug-resistant partial seizures (with/without SGS) to perampanel 2, 4, 8, or 12 mg or placebo for double-blind treatment. The adverse event (AE) of falls was analyzed in the Safety Analysis Set (N = 1480). Study 332 randomized subjects aged ≥12 years with a diagnosis of PGTCS into perampanel 8 mg or placebo groups for double-blind treatment. In a systematic review of reported falls in the study 332 Safety Analysis Set (N = 163), falls were queried to establish whether each was seizure related; subjects with falls resulting from a seizure were not included in this analysis. Results: For studies 304/305/306, treatment-emergent falls occurred in 5.1% perampanel-treated versus 3.4% placebo-treated subjects with partial seizures. Exposureadjusted rate for falls (falls/subject-month of exposure) was greater for total perampanel than for placebo (0.0175 vs. 0.0093) and was dose related for those receiving perampanel. In subjects with SGS, incidence of treatment-emergent falls was 4.3% in perampanel and 4.0% in placebo groups. Exposure-adjusted rates were 0.0169 and 0.0097 falls per subject-month of exposure in perampanel and placebo, respectively. For study 332, 2.5% perampanel-treated and 1.2% placebo-treated subjects with PGTCS had treatment-emergent falls that were not part of a seizure. Exposureadjusted rates were 0.0169 and 0.0032 falls per subject-month of exposure in perampanel and placebo, respectively. Significance: Results of the perampanel studies suggest that patients with epilepsy should be monitored due to the common risk of falls.
of falls. 8 In addition, although gait disturbance is common in the elderly, it may be increased in patients taking AEDs. 10 Perampanel is a selective, noncompetitive a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-receptor antagonist approved for adjunctive treatment of partial seizures with or without secondarily generalized seizures (SGS) and for primary generalized tonic-clonic seizures (PGTCS) in patients aged 12 years or older with epilepsy. 11 The safety and tolerability of adjunctive perampanel in subjects with drug-resistant partial seizures have been demonstrated in three multicenter, double-blind, randomized, placebo-controlled phase III studies (studies 304, 305, and 306) conducted between April 2008 and January 2011. [12] [13] [14] In a recent phase III, double-blind study (study 332), adjunctive perampanel treatment was well tolerated and improved seizure control in subjects with drug-resistant PGTCS. 15 In the phase III studies of perampanel in partial seizures, the incidence of treatment-emergent falls was reported and used in the analysis regardless of whether the falls were the result of a seizure. Therefore, in study 332 in subjects with PGTCS, to distinguish seizure-associated events from independent ones, a systematic review of reported events of falls was conducted, and queries were sent back to the investigator to establish whether the fall was related to a seizure or not; subjects who had falls as a result of a seizure were not included in this analysis. Herein we report the results of subjects receiving perampanel for treatment of partial seizures or PGTCS to determine whether treated subjects have an increased rate of falls.
Methods
For each study, the analysis of falls is presented with the number of subjects who had falls and the exposure-adjusted rate of falls.
Study design and subjects with partial seizures
The design of the three, phase III studies of perampanel (study 304, NCT00699972; study 305, NCT00699582; and study 306, NCT00700310) has been described in detail elsewhere. [12] [13] [14] Following the 6-week Baseline Period, subjects were randomized to placebo or perampanel 2, 4, 8, or 12 mg. [12] [13] [14] In each study, subjects entered the Pre-randomization Phase and were assessed for baseline seizure frequency and eligibility for the 19-week, double-blind Treatment Phase. During the 6-week Titration Period, daily perampanel doses were increased by 2 mg/week until the randomized dose or intolerability was reached. Subjects continued on the dose achieved during titration throughout the 13-week Maintenance Period and continued receiving their established concomitant AEDs without modification. Subjects who discontinued treatment or who did not enter the Extension Study had a follow-up visit 4 weeks after the end of therapy. [12] [13] [14] Eligible subjects included those aged 12 years or older, diagnosed with partial seizures with or without secondary generalization in accordance with the 1981 International League Against Epilepsy (ILAE) Classification of Epileptic Seizures, 16 who had at least two AEDs failures, and who had five or more partial seizures during baseline. Subjects must have been on stable doses of up to three approved AEDs with or without vagus nerve stimulation for at least 3 weeks before randomization. [12] [13] [14] The Safety Analysis Set included subjects who took at least one dose of study drug and had at least one safety assessment after taking the first dose of study drug in the three phase III studies. Falls and injuries from the 1,480 subjects were stratified based on occurrence with concurrent seizures (defined as seizures on the same date of adverse event [AE] onset) and nonconcurrent seizures (defined as no seizure on the date of AE onset). In cases where there were incomplete onset dates recorded for falls (that is, month only, with date missing), they were counted as nonconcurrent events. Additional exposure-adjusted analyses based on number of events, rather than number of subjects, were also performed. Statistical significance was not determined in this post hoc analysis.
Study design and subjects with PGTCS
Between July 2011 and May 2014, the phase III study to evaluate the efficacy and safety of adjunctive perampanel in PGTCS (study 332, NCT01393743) was conducted; it has been described in detail elsewhere. 15 Briefly, the Pre-randomization Phase consisted of two periods: Screening (up to 4 weeks) and Baseline (4 or 8 weeks, depending on the accuracy of diary-documented seizures during Screening), during which subjects were assessed for eligibility to participate in the study. The Randomization Phase consisted of three periods: Titration (4 weeks), Maintenance (13 weeks), and Follow-up (4 weeks; only for those subjects not entering the Extension Phase). At the start of the
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• Results of the perampanel studies suggest that patients with epilepsy should be counseled and monitored due to the risk of falls Randomization Phase, eligible subjects were randomized to the perampanel or placebo treatment groups in a 1:1 ratio. During the 4-week Titration Period, subjects initially received perampanel 2 mg/day or matching placebo and were uptitrated weekly in 2 mg increments to a target dose of 8 mg/day or the highest tolerated dose. At the completion of the Titration Period, subjects entered the 13-week Maintenance Period on the last dose level achieved at the end of the Titration Period and continued taking this dose once daily for the duration of the Maintenance Period.
Eligible subjects ≥12 years of age (18 years of age or older in Germany; <65 years of age in India) had a clinical diagnosis of PGTCS in the setting of idiopathic generalized epilepsy according to the 1981 and the 1989 ILAE classifications, 16, 17 and diagnosis was confirmed by independent reviewers from the Epilepsy Study Consortium. 15 In addition, subjects had routine electroencephalography within 5 years prior to or during the Baseline Period showing features consistent with primary generalized epilepsy; experienced three or more PGTCS during the 8-week period prior to randomization; and were taking fixed doses of one to three concomitant AEDs for a minimum of 30 days prior to Baseline, which they continued throughout the study (only one inducer AED was allowed; i.e., carbamazepine, oxcarbazepine, or phenytoin).
The Safety Analysis Set included subjects (N = 163) who took at least one dose of study drug and had at least one safety assessment after taking the first dose of study drug in the study. To distinguish seizure-associated falls from independent ones, a systematic review of reported falls was conducted, and queries were sent back to the investigator to establish whether the fall was related to a seizure. Falls that occurred as part of a PGTCS were excluded from this analysis. Additional analyses on the exposure-adjusted rates of falls were also performed. Statistical significance was not determined in this post hoc analysis.
Pharmacokinetic/pharmacodynamic analyses
Population pharmacokinetic (PK) analysis was performed on perampanel plasma steady-state concentration data in subjects from study 332 (PGTCS) and from studies 304, 305, and 306 (partial seizures). The perampanel pharmacokinetics was not affected by seizure type, 18 and in study 332 the relationship between perampanel concentrations and safety was evaluated only for certain treatmentemergent adverse events (TEAEs) (e.g., hostility/aggression and psychosis/psychotic events). Thus, the perampanel PK and pharmacodynamics (PD) presented in this current analysis include only the pooled data from the three phase III studies in subjects with partial seizures. Plasma samples for bioanalysis of perampanel were collected during the Maintenance Period weeks 10, 14, and 19 of treatment and at the follow-up visit (week 23) or at the discontinuation visit. The average seizure frequency over 28 days during the Maintenance Period was used for PK/PD analysis of the relationship between exposure and response. The investigators recorded spontaneously reported AEs or serious AEs (SAEs). The occurrence and duration of the AEs were used for the analysis of the exposure-AE relationship. The probability of occurrence of a given AE was estimated using a logistic regression model with SAS version 8.2 (SAS Institute, Cary, NC, U.S.A.). A linear predictor (logit) was estimated as a function of exposure (average concentration of perampanel at steady state; C avss ) to perampanel.
Results

Partial seizures
A total of 75 (5.1%) of the 1480 subjects enrolled in the phase III partial seizure studies experienced at least one fall during the studies. Ten (0.7%) subjects had falls during the Prerandomization Phase before receiving study drug, and three of these also had falls during the Titration and/or Maintenance Periods. Falls occurred in 2.1% of subjects during the 6-week Titration Period, 2.8% of subjects during the 13-week Maintenance Period, and 0.2% of subjects during the Follow-up Phase. Most of the subjects who had falls were taking two (52%) or three (40%) concomitant AEDs at baseline. A similar number of male (n = 36) and female (n = 39) subjects experienced falls during the study. Compared with those who did not experience falls, subjects with falls had a longer mean duration since diagnosis of epilepsy (25.6 vs. 21.1 years) and were older (mean age 39.8 vs.
years).
Treatment-emergent falls during the double-blind treatment phase (Titration and Maintenance) occurred in 5.1% (n = 53) of subjects treated with perampanel compared with 3.4% (n = 15) receiving placebo ( Table 1 ). The three subjects who had falls during the Prerandomization Period were randomized to 8 mg (n = 1) and 12 mg (n = 2) perampanel. For subjects with a TEAE of falls, there were a total of 73 falls during the double-blind treatment phase in the 53 perampanel subjects and 17 falls in the 15 placebo subjects. The exposureadjusted rate for falls (falls/subject-months of exposure) during the double-blind studies was greater for subjects treated with perampanel than for those treated with placebo (0.0175 vs. 0.0093). The exposure-adjusted rate for falls in the perampanel-treated subjects was dose related (Fig. 1A) : the rate in the lowest dose groups (perampanel 2 and 4 mg) was below that of placebo, and the rate at the higher doses (perampanel 8 and 12 mg) was greater than placebo.
In comparing concomitant AEDs for perampanel-and placebo-treated subjects who had falls, the proportion of subjects on enzyme-inducing AEDs was similar in the perampanel (55%) and placebo (53%) groups, as was the proportion of subjects receiving two (49% vs. 53%) or three (42% vs. 40%) AEDs. The most common AEDs in the placebo group were lamotrigine (47%), pregabalin (33%), levetiracetam (27%), carbamazepine (27%), and clonazepam (20%). For the perampanel group, the most common AEDs were levetiracetam (36%), valproic acid (28%), lamotrigine (26%), carbamazepine (26%), phenytoin (19%), and topiramate (19%).
In subjects aged <18 years (adolescents) and 18 to <65 years (adults), falls occurred slightly more frequently in the perampanel-treated subjects than in the placebo-treated subjects (adolescents, perampanel 3.1% vs. placebo 2.2%; adults, perampanel 4.9% vs. placebo 3.6%). However, among the small number of subjects aged ≥65 years (elderly, n = 28; 20 perampanel-treated, 8 placebo-treated), the difference between perampanel and placebo was more pronounced (perampanel 25% vs. placebo 0%; Table S1 ). Although the sample size for elderly subjects treated with perampanel was small, these subjects had an increased risk of falls (25%) compared with younger adults (4.9%) and adolescents (3.1%). 11 As shown in Table 1 , most subjects had treatment-emergent falls that were considered as mild (n = 32 perampanel; n = 10 placebo) or moderate (n = 19 perampanel; n = 5 placebo) in severity, and not related (n = 34 perampanel; n = 12 placebo) or possibly related (n = 18 perampanel; n = 3 placebo) to study drug. In the perampanel group, two falls were considered severe in one subject treated with perampanel 8 mg and one treated with perampanel 12 mg; only one (12 mg) was probably related to study drug. Neither of these severe falls was the primary reason for discontinuation. A TEAE of fall leading to discontinuation did occur in two subjects receiving perampanel 12 mg (Table 1) . One of these subjects was aged ≥65 years and withdrew from the study due to a serious TEAE (SAE) of fall. Study drug interruption or dose reduction was caused by a TEAE of fall in three subjects (0.3%): one subject (0.2%) in the perampanel 8 mg group and two subjects (0.8%) in the perampanel 12 mg group.
In both perampanel and placebo groups, the overall rate of falls in subjects who experienced concurrent seizures (same date as onset of falls) was notably higher than that in subjects who experienced nonconcurrent seizures (Fig. 1B) . The incremental rate for subjects on perampanel above the rate for those on placebo (that is, the difference) was nearly identical for those with concurrent and nonconcurrent seizures. In subjects with concurrent seizures, the exposureadjusted event rates for falls showed a dose-response relationship by the actual dose taken at event onset: 0.0027, 0.0028, 0.0137, and 0.0200 for perampanel doses of 2, 4, 8, and 12 mg, respectively. Subjects with nonconcurrent seizures also showed a dose-response relationship, although it was lower: the exposure-adjusted event rates were 0, 0.0014, 0.0068, and 0.0116 for perampanel doses of 2, 4, 8, and 12 mg, respectively.
Five subjects had TEAEs of fractures (of the wrist, fibula, tibia, and spine) that occurred on the same day as falls (three perampanel vs. two placebo subjects; Table 2 ). Of these, four subjects were female, one subject was aged ≥65 years, and two subjects discontinued the study due to the fall and fracture. Of the three perampanel subjects, the last dose of perampanel was 4 mg (n = 2) and ≥8-12 mg (n = 1). For four of the five subjects who had falls and fractures on the same day, there was no report of a seizure on the same day. For one subject who was randomized to placebo, the seizure status on the day of the fall and fracture (spinal) was unknown.
Further analysis of falls was carried out for the subjects in the three partial seizure studies who had SGS (N = 391 perampanel; N = 173 placebo). Five subjects had falls prior to randomization, 12 subjects had falls during the Titration Period, 15 subjects had falls during the Maintenance Period, and one subject had a fall during the Follow-up Phase. A total of 17 perampanel-treated subjects reported 27 falls, and 7 placebo-treated subjects had 7 falls during the doubleblind treatment phase. In the majority of subjects with falls, the falls occurred at the 8 mg perampanel dose (three subjects during Titration and seven during the Maintenance Period). The exposure-adjusted rate for falls (falls/subjectmonths of exposure) during the double-blind studies only for subjects with SGS was greater for subjects treated with perampanel than for those treated with placebo (0.0169 vs. 0.0097) (Fig. 2) . None of the falls in subjects with SGS was considered an SAE. One subject (a 24-year-old man) reached a dose of 4 mg and was discontinued during the Titration Period of the study because of the event of the fall and its consequences (skin laceration and spinal fracture). One subject (37-year-old man) had his 8 mg perampanel dose reduced during the Maintenance Period due to the TEAE of fall.
Primary generalized tonic-clonic seizures
Of the 163 subjects in the Safety Analysis Set, 2 (2.5%) of the 81 perampanel-treated and one (1.2%) of the 82 placebo-treated subjects had TEAEs related to falls that were not part of a seizure. The two perampanel-treated subjects had a total of five falls during treatment. One was a male subject who had one fall during the Maintenance Period on Seizure status during fall was unknown for three subjects (n = 1 PBO; n = 2 PER). N, number of subjects; n, number of falls; PBO, placebo; PER, perampanel; TEAE, treatment-emergent adverse event. Dose groups based on the actual treatment groups. Epilepsia ILAE day 113 (dose 6 mg) and was receiving phenobarbital, valproic acid, and clobazam at the time of the fall. The other subject (a female who also had three falls during prerandomization) had a total of four falls; one fall during the Titration Period on day 8 (dose 4 mg); one on day 29 (dose 8 mg) and one on day 46 (dose 8 mg), both during the Maintenance Period; and one on day 117 (23 days after last dose). These five falls in the perampanel-treated subjects did not lead to discontinuation, were not considered to be related to study drug, and were reported as mild or moderate ( Table 1 ). The subject was receiving valproic acid and phenytoin at the time of the falls. The placebo-treated subject was female and had one fall during the Maintenance Period (day 75) that resulted in superficial bruising and hospitalization. X-rays were performed and she was instructed to wear a cervical brace; the fall was considered an SAE. The subject was also receiving lorazepam, zonisamide, and topiramate at the time of the fall. The exposure-adjusted rates of fall were 0.0169 and 0.0032 per subject-month of exposure in perampanel and placebo, respectively (Fig. 3) .
PK/PD and the occurrence of falls
The PK/PD population included in this analysis consisted of 1,109 subjects from the pooled, phase III partial seizure studies (n = 770 perampanel-treated, n = 339 placebo-treated). For this analysis, gait disturbance was grouped with balance disorders and falls. The probability of occurrence of gait disturbance increased with increasing plasma perampanel concentrations. Summary statistics of average perampanel concentration at steady state, C avss , suggest that median predicted perampanel concentrations are greater in subjects with gait disturbance (383 ng/ml) than in those without (211 ng/ml). As shown in Figure 4 , the predicted median C avss showed a dose response.
Discussion
This post hoc analysis examined the occurrence of falls in the phase III, double-blind clinical studies of perampanel among subjects with drug-resistant partial seizures with or without SGS and in subjects with PGTCS. Data from the analysis for subjects with partial seizures suggest that perampanel exposure is related to falls and to fall-related TEAEs (with and without concurrent seizures), and increased falls are associated with increased dose. Indeed, the incidence and severity of the falls, as well as the number of falls leading to discontinuation, were greater in subjects treated with 8 and 12 mg of perampanel. All falls were captured, regardless of whether they were the result of a seizure, but the incremental risk of perampanel on the occurrence of falls was the same in both groups. In the PGTCS study, falls were systematically reviewed to include only those not associated with a seizure event; although the number of falls was low, the results of the perampanel studies suggest that patients with epilepsy should be counseled and monitored due to the risk of falls.
Several studies have demonstrated that AEDs can be associated with a fall risk. 6, 7, [19] [20] [21] In this post hoc analysis of the phase III clinical trials, dizziness, ataxia, balance disorder, and gait disturbance were spontaneously reported as Perampanel phase III partial seizure studies -SGS: Exposureadjusted rates for TEAEs of falls during the double-blind phase (titration and maintenance) for the Safety Analysis Set. a One month = 30 days. N, number of subjects; n, number of falls; PBO, placebo; PER, perampanel; SGS, secondarily generalized seizures; TEAE, treatment-emergent adverse event. Epilepsia ILAE separate TEAEs in perampanel-treated subjects with falls and without falls, but the incidences were greater in subjects with falls. The PK/PD results of the present analysis from the pooled phase III studies in partial seizures suggest that the probability of occurrence of gait disturbance, including falls and balance disorders, is increased in patients who have higher plasma perampanel concentrations. Indeed, a predictable dose-plasma concentration relationship exists for perampanel, and the probability of AEs has been shown to increase with higher perampanel concentrations. 22 The exposure-adjusted rate of falls was also shown to be greatest with perampanel for subjects with partial seizures, and specifically at 8 and 12 mg. These results show that higher doses of perampanel may increase the risk of falls.
In patients with epilepsy, seizures can cause falls, which may in turn increase the risk of physical injuries. 23 Head injuries are commonly associated with seizures due to the loss of consciousness and inhibition of protective reflexes. 24 Among the seizure types associated with idiopathic generalized epilepsy, the features of tonic-clonic seizures result in an increased risk of falls and injuries secondary to the seizure. 23 Previous studies examining patients at outpatient clinics show that fractures and seizure-related injuries are more frequent in patients with generalized tonic-clonic seizures. 25, 26 In the partial seizure studies, falls were more common in subjects who had concurrent seizures, regardless of whether the subject was receiving perampanel or placebo. The direct effect of perampanel (that is, increased incidence of falls) seems to be similar in those with concurrent and nonconcurrent seizures. In contrast, for the PGTCS studies, treatment-emergent falls were systematically reviewed, and only falls that were not part of a seizure event were included in the analysis. Falls occurred in two perampanel-treated subjects and one placebo-treated subject. One perampaneltreated subject had numerous falls, and the exposureadjusted rate of falls was also shown to be greatest with perampanel treatment. Although the falls in subjects with partial seizures with secondary generalization were captured differently from those with PGTCS, the exposure-adjusted rate was similar for perampanel-treated subjects and always higher than in placebo groups.
Three perampanel-treated and two placebo-treated subjects with partial seizures who experienced falls also had fractures on the same day. Because all falls were captured, it is difficult to ascertain whether the fall was seizure related and ultimately led to the fracture. In the PGTCS study, in which only falls that were not seizure related were analyzed, Epilepsia ILAE Figure 4 . Summary statistics of modelpredicted perampanel concentration (C avss ) in perampanel-treated subjects with and without gait disturbance (including balance disorders and fall) in the PK/PD population from the pooled phase III partial seizure studies. C avss , average perampanel concentration at steady state; N, number of subjects with plasma concentration data; PER, perampanel. Epilepsia ILAE none of the subjects had fractures as a result of the fall, although the placebo-treated subject did have a cervical injury and needed to wear a brace. Shiek Ahmad and colleagues showed that patients treated with AEDs experiencing seizures have rates of falls similar to those without seizures, 19 whereas Persson et al. 26 showed that less than half of fractures are directly related to seizures. These studies by Shiek Ahmad et al. and Persson et al. included participants in outpatient clinics and did not directly examine TEAEs related to falls in a randomized controlled trial. In addition, fractures, not falls, related to seizures were specifically examined, 26 even if falls may be implied as the specific cause of injury.
Elderly subjects treated with perampanel in this study did have an increased risk of falls. This is in agreement with other studies showing that AEDs may contribute to gait disturbance and falls, particularly in the elderly population. 10 In addition, elderly patients have an increased risk of clinically important drug interactions and AEs due to the frequent use of several drugs to treat multiple morbidities. 27 In a recent publication, Isojarvi et al. 28 suggest that the reduction of seizure-related injuries in patients with Lennox-Gastaut syndrome taking clobazam is clinically meaningful beyond just the concurrent reduction in seizure frequency. Indeed, reducing the morbidity associated with seizures is important for quality of life of patients with epilepsy. Reducing seizure frequency is also vital, especially in generalized tonic-clonic seizures, as it is a risk factor for sudden unexpected death in epilepsy (SUDEP). 29 In patients with partial seizures (with and without secondarily generalized seizures) and PGTCS, four phase III clinical studies show that adjunctive perampanel treatment is efficacious and well tolerated. [12] [13] [14] [15] Although falls were numerically higher with perampanel treatment in these studies, the majority of falls in patients with partial seizures were considered mild (32 of 53 patients) or moderate (19 of 53), with 2 patients discontinuing the study due to falls. There were no patients with PGTCS who discontinued due to a fall.
Limitations of the studies incorporated in this analysis include potential confounders that were not adjusted for, such as smoking, alcohol use, or other sociodemographic factors that may contribute to falls. Although study 332 in subjects with PGTCS aimed to systematically review falls to include only those not associated with a seizure event, there is the potential for inaccuracy by subjects with regard to recalling falls and concomitant seizures.
Results of this post hoc analysis of the phase III doubleblind studies demonstrate that similar to other AEDs, 19 perampanel increases the risk of falls. Falls can be a consequence of the seizure itself and/or can result from the side effects of AEDs. Clinicians need to be aware of and counsel patients about the potential for an increased risk of falls when treating with perampanel, especially at higher doses. Despite the risk of increased falls, particularly in the elderly, higher doses of perampanel have been shown to provide a benefit in seizure control by reducing seizure frequency. [12] [13] [14] Appropriate treatment should be individualized by taking the patient profile into consideration.
